New Chronic Myelogenous Leukemia Study Findings Have Been Reported by Investigators at Guangzhou Medical University (Piperlongumine Overcomes Imatinib Resistance By Inducing Proteasome Inhibition In Chronic Myelogenous Leukemia Cells).

Předmět:	CHRONIC myeloid leukemia IMATINIB MEDICAL sciences MYELOID leukemia PROTEIN-tyrosine kinase inhibitors
Zdroj:	Drug Week; 2/3/2023, p789-789, 1p
Abstrakt:	Keywords: Guangzhou; People's Republic of China; Asia; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Cancer; Chronic Myelogenous Leukemia; Drugs and Therapies; Health and Medicine; Hematology; Imatinib Therapy; Leukemia; Myelogenous Leukemia; Oncology; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN Guangzhou People's Republic of China Asia Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Cancer Chronic Myelogenous Leukemia Drugs and Therapies Health and Medicine Hematology Imatinib Therapy Leukemia Myelogenous Leukemia Oncology Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 2023 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Chronic Myelogenous Leukemia are discussed in a new report. Guangzhou, People's Republic of China, Asia, Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Cancer, Chronic Myelogenous Leukemia, Drugs and Therapies, Health and Medicine, Hematology, Imatinib Therapy, Leukemia, Myelogenous Leukemia, Oncology, Pharmaceuticals, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu